WCM Investment Management LLC Boosts Stock Holdings in Kymera Therapeutics, Inc. $KYMR

WCM Investment Management LLC grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 44.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 152,381 shares of the company’s stock after buying an additional 47,187 shares during the quarter. WCM Investment Management LLC’s holdings in Kymera Therapeutics were worth $12,111,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in KYMR. SG Americas Securities LLC grew its holdings in Kymera Therapeutics by 169.1% in the fourth quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock valued at $1,766,000 after purchasing an additional 14,261 shares during the last quarter. Hudson Bay Capital Management LP grew its holdings in shares of Kymera Therapeutics by 362.7% during the third quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock worth $1,309,000 after buying an additional 18,134 shares in the last quarter. Vanguard Group Inc. raised its holdings in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares during the last quarter. Eagle Health Investments LP purchased a new position in Kymera Therapeutics during the fourth quarter worth about $10,606,000. Finally, Maven Securities LTD purchased a new position in shares of Kymera Therapeutics during the 4th quarter worth about $1,167,000.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. B. Riley Financial raised their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Royal Bank Of Canada downgraded shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and boosted their target price for the stock from $106.00 to $115.00 in a research report on Monday, July 13th. Finally, Morgan Stanley reissued an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Twenty analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $122.64.

Kymera Therapeutics Stock Down 4.1%

Kymera Therapeutics stock opened at $111.06 on Tuesday. Kymera Therapeutics, Inc. has a 52-week low of $36.65 and a 52-week high of $130.05. The firm has a market capitalization of $9.14 billion, a price-to-earnings ratio of -31.11 and a beta of 1.95. The firm has a 50-day moving average price of $94.06 and a two-hundred day moving average price of $85.64.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.82) earnings per share. Research analysts expect that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 77,109 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the sale, the chief financial officer owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. The trade was a 23.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bruce Booth sold 467,878 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the completion of the sale, the director directly owned 472,267 shares of the company’s stock, valued at $52,086,327.43. The trade was a 49.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,644,113 shares of company stock worth $390,820,176 in the last 90 days. Corporate insiders own 15.98% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.